Journal
PHARMACEUTICALS
Volume 14, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/ph14040305
Keywords
mild cognitive impairment (MCI); mild dementia; Alzheimer's disease; Ginkgo biloba (Egb761 (R)); Tebonin; anti-dementia drugs; randomized controlled trials
Categories
Funding
- Italian Ministry of Health
Ask authors/readers for more resources
Ginkgo biloba leaf special extract EGb 761(R) has demonstrated effectiveness in improving cognitive function and neuropsychiatric symptoms in patients with age-related cognitive decline, MCI, and mild to moderate dementia, reducing caregiver stress and maintaining patient autonomy. Further evidence is needed to evaluate the role of EGb 761(R) in combination therapy with anti-dementia drugs.
Mild cognitive impairment (MCI) and dementia are clinically prevalent in the elderly. There is a high risk of cognitive decline in patients diagnosed with MCI or dementia. This review describes the effectiveness of Ginkgo biloba leaf special extract EGb 761(R) for the treatment of dementia syndromes and EGb 761(R) combination therapy with other medications for symptomatic dementia. This drug has shown convincing results, improving cognitive function, neuropsychiatric symptoms and consequent reduction of caregiver stress and maintenance of autonomy in patients with age-related cognitive decline, MCI and mild to moderate dementia. Currently, there is little evidence to support the combination therapy with anti-dementia drugs and, therefore, more evidence is needed to evaluate the role of EGb 761(R) in mixed therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available